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Transgenic Bacillus thuringîensis 
James A. Baum 
Ecogen Inc. Langhorne, PA, USA 
Research Challenges and Needs for 
Safe Use of Transgenic Organisms 
INTRODUCTION 
Bacillus thuringiensis (Bt) continues to 
be the world's most successful biolog-
ical pesticide. Currently, there are over 
200 fîf-based bioinsecticide products 
registered with the U. S. Environmental 
Protection Agency for the control of 
lepidopteran, dipteran, and coleopter-
an pests. While the vast majority of 
thèse registrations are for naturally 
occurring Bts, transconjugant Bts and 
Bts modified by recombinant DNA tech-
nology hâve been registered as active 
ingrédients. 
As a source of gènes for insecticidal 
proteins, B. thuringiensis has no peer. 
Corporate, institutional, and govern-
ment strain collections of B. thuringien-
sis contain thousands of strain isolâtes 
from around the world. The rapid 
growth in the number of new insecti-
cidal crystal protein {cry) gènes report-
ed in the scientific and patent literature 
over the past several years, due largely 
to the gène discovery programs of com-
panies involved in fît bioinsecticide and 
transgenic plant development, has 
prompted the adoption of a new no-
menclature System that categorizes the 
encoded Cry proteins on the basis of 
amino acid séquence identity rather 
than on insecticidal activity (1). The 
Cry proteins of B. thuringiensis, also 
referred to as 8-endotoxins, comprise a 
diverse group of insecticidal agents. 
Presently, there are -80 différent class-
es/subclasses of Cry proteins, represent-
ing at least four distinct protein families 
that hâve apparently co-evolved toxic-
ity towards insects. The rapid pace of 
Cry protein discovery can be followed 
by visiting the Bt gène nomenclature 
home page at the following URL: http: 
/ / w w w . b i o l s . s u sx . a c . u k / H orne / 
Neil_Crickmore/Bt/. 
This remarkable diversity of insecti-
cidal traits has fueled research and de-
velopment programsto engineer insect-
resistant plants expressing modified cry 
gènes. Although the commercial intro-
duction of transgenic crops such as 
cotton and corn in the U. S. has eroded, 
to some extent, the market for foliar-
applied Bt bioinsecticides, the rowcrop 
markets hâve never been a major mar-
ket for thèse insecticides. In agricul-
ture, Bt bioinsecticides continue to be 
important in vegetable and tree fruit 
and nut markets and as tools for inte-
grated pest management. 
OPPORTUNITIES 
FOR IMPROVING 
B. THURINGIENSIS 
BIOINSECTICIDES 
The mode of action of B. thuringiensis 
as an insecticide is recognized to be 
complex, involving the contribution of 
individual Cry proteins, non-crystal 
forming insecticidal proteins, and syn-
ergistic interactions among Cry proteins 
and between Cry proteins and the spore. 
Thus, there are many components that 
détermine the insecticidal potency of 
B. thuringiensis. While potency is crit-
ical, the success of a Bt bioinsecticide 
is also dépendent on a number of other 
factors including crystal protein yield 
in fermentation, cost-of-production, 
handling properties of the formulated 
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product, formulation components to im-
prove foliar coverage and persistence, 
and product stability while in invento-
ry. Of thèse, insecticidal potency and 
Cry protein yield and stability can be 
improved through genetic manipula-
tion. 
Currently registered B. thuringiensis 
products employ only a fraction of the 
known Cry proteins. The utility of many 
of thèse new proteins for insect control 
and the benefits of employing spécifie 
Cry protein compositions remains to be 
determîned. Accordingly, there is little 
incentive to introduce foreign insecti-
cidal gènes into B. thuringiensis when 
so few of its native cry gènes hâve been 
evaluated for commercial use. 
Early attempts to improve Bt bioin-
secticides relied on a conjugation-like 
process to transfer large cry plasmids 
from one strain to another. The utility 
of conjugal transfer is limited, howev-
er, because 1) the majorityof cry gènes 
cannot be readily transferred by this 
process, 2) spécifie cry gène combina-
tions cannot be made, 3) cry gènes 
modified for improved activity or sta-
bility cannot be exploited. Advances in 
molecular biology, the isolation of new 
c/ygenes, and a superficial understand-
ing of Cry protein structure and func-
tion hâve together provided opportuni-
tés for improving Bt strains through 
more direct genetic manipulation. 
BIOINSECTICIDES BASED 
ON RECOMBINANT 
B. THURINGIENSIS STRAINS 
00 
o> 
^ Three B. thuringiensis strains modified 
•^ through recombinant DNA techniques 
g. hâve been registered as active ingredi-
w ents wi th the U. S. EPA.: EG7673 
£ (Raven™ OF bioinsecticide), EG7841 
z (CRYMAX™ WDG/WP bioinsecticide), 
2 and EG7826 (Lepinox™ WDG/G bioin-
o secticide). In developing thèse genet-
H ically-modified Bts, Ecogen Inc. decid-
§ ed to take a conservative approach to 
Q facilitate timely regulatory approval and 
£ public acceptance: 1) The Bt strains 
x are derived from isolâtes of the subspe-
cies kurstaki, the same subspecies 
used in the production of DIPEL™, Jav-
elin™, and a host of other Bt products; 
2) EG7673 and EG7826 are derivatives 
of the previously registered transconju-
gant Bt strains EG2424 and EG2348, 
respectively; 3) The cloned insecticidal 
gènes introduced into thèse strains 
are derived from B. thuringiensis; and 
4) An indigenous site-specifîc recombi-
nation System was use to delete ail 
foreign DNA éléments, including anti-
biotic résistance gènes, from the recom-
binant cryplasmids aftertheir introduc-
tion into Bt, thus making the modified 
Bts essentially non-transgenic (2). 
EG7673 contains both a cry3Bb and 
a cry3Aa gène and is a cost-effective 
producer of toxins active against Colo-
rado potato beetle larvae. The lepi-
dopteran-toxic EG7841 construct 11831 
and EG7826construct11097 differ from 
EG7673 in that they contain cry gènes 
modified for improved insecticidal ac-
tivity. The crv7Cgene in EG7841 con-
struct 11831 contains a mutation that 
results in improved toxicity towards the 
beet armyworm, Spodoptera exigua. 
The cry1Ac/1Fgène in EG7826 construct 
11097 encodes a chimeric toxin with 
superior toxicity to the fall armyworm, 
S. frugiperda, when compared to the 
parental CrylAc and CrylF toxins. 
The Raven, CRYMAX, and Lepinox 
registration packages prepared for 
submission to the U. S. EPA. were no 
différent than those required for natu-
rally-occurring Bts. In ail three cases, 
regulatory approval was obtained ap-
proximately one year after the date of 
submission. 
Thèse genet ical ly-modi f ied Bts, 
though not strictly transgenic organ-
isais, provide an example of how a 
conservative approach to genetic ma-
nipulation can facilitate commercial 
application. For instance, it is not known 
what risks, if any, there are in the 
widespread application of recombinant 
microorganisms containing transmissi-
ble antibiotic résistance gènes. Some 
commentators hâve insisted there are 
no significant risks, yet history is re-
plète with examples of the unintended 
conséquences of technology. For Eco-
gen, deletion of thèse unwanted DNA 
128 
éléments from commercial recombinant 
Bts strains made good sensé if only 
because it removed this issue from 
considération. It is reasonable to con-
clude that this strategy contributed to 
the prompt regulatory approval of thèse 
recombinant Bts. Similarly, the use of 
native insecticidal gènes was important: 
the crylC variant in CRYMAX and the 
hybrid cry gène in Lepinox were readily 
approved because thèse gènes, al-
though modified by recombinant DNA 
techniques, are derived from B. thur-
ingiensis cry gènes. As a resuit, several 
unique bioinsecticide products hâve 
now entered the marketplace (3). 
A SAMPLING OF RESEARCH 
NEEDS AND ISSUES 
Safety 
Concerns hâve been raised about the 
safety of fîf-based bioinsecticides de-
spite their long history of safe use. This 
pertains to Bts in gênerai, recombinant 
or otherwise. For instance, the closely 
related species Bacillus cereus can 
cause food poisoning and at least some 
of the enterotoxin gènes implicated in 
this pathology are reported to be présent 
in B. thuringiensis. Similarly, a récent 
study suggested that an obscure sub-
species of B. thuringiensis could act as 
an opportunistic pathogen in immuno-
compromised individuals. While this 
may be only guilt-by-association, it does 
suggest that there are rare instances 
where B. thuringiensis could be any-
thing but harmlessto humans. Finally, 
the présence of spores in most Bt bio-
insecticide products has been cited as 
a possible health risk although little data 
has been presented to support this 
notion. How important are thèse con-
cerns in light of the obvious benefits of 
Bt bioinsecticides and their long history 
of safe use? 
Insect résistance 
Insect résistance development will con-
tinue to be a concern, and not just 
because of the widespread cultivation 
of insect-resistant plants expressing cry 
gènes. The diamondback moth, Plutel-
la xylostella, has developed résistance 
to certain Cry1 proteins because of the 
extensive use of Bt bioinsecticides. 
Thus, there is an ongoing need to iden-
tify novel insecticidal proteins from B. 
thuringiensis as well as to evaluate the 
insecticidal properties of the many Cry 
proteins that hâve recently been de-
scribed. Individual gènes could be readi-
ly introduced into appropriate Bt host 
strains by recombinant DNA techniques 
and evaluated for efficacy. 
Use of novel insecticidal proteins 
As noted above, the majority of known 
Bt Cry proteins hâve not been utilized 
as active ingrédients in bioinsecticide 
products. Certainly, some of thèse 
proteins, a number of which are phylo-
genetically distinct from the commonly 
used Cry proteins, will be deployed in 
bioinsecticide products or expressed in 
planta. This introduces a problem: the 
"long history of safe use" cited for B. 
thuringiensis actually relates to a small 
number of Bt strains producing a small 
fraction of the known crystal proteins. 
In the absence of any studies delineat-
ing their mode of action, to what extent 
should novel Cry proteins (or even Bt 
strains) be regarded as safe? 
Foreign gènes 
Ultimately, the quest to improve bioin-
secticides may lead to the introduction 
of foreign insecticidal gènes into B. 
thuringiensis. Récent studies indicate 
that B. thuringiensis can transfer genet-
ic information to other bacilli in soil and 
within the hoemocoel of infected in-
sects (4). Obviously, some thought 
should be given to how this transfer 
could be limited, perhaps through the 
use of sporulation-déficient variants of 
B. thuringiensis. Aside from the issue 
of horizontal gène transfer, how should 
the regulatory requirements for a trans-
genic Bt differ from those of other re-
combinant Bts? 
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